MET as a NSCLC Target
Podcast | English | 2022 | 46 Min
Image For Activity Cover
No Credit Offered
This episode of Lung Cancer Considered covers a subset of patients with non-small cell lung cancer with lung cancer -- MET exon 14 skipping mutations. MET exon 14 skipping mutations occur in approximately 3 to 4% of patients with NSCLC, typically in the absence of other driver mutations. Host Dr. Narjust Florez will discuss the unique clinical issues surrounding MET exon with Dr. Ross Camidge, Director of the Clinical and Research Thoracic Program at the University of Colorado and Dr. Noemi Reguart, Clinical Professor at the University of Barcelona.
Dr. Narjust Florez
Dr. Ross Camidge
Dr. Noemi Reguart
Powered By